# Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

> **NCT04724928** · PHASE2 · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 156 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma

## Interventions

- **RADIATION:** Metastasis directed therapy (MDT)
- **DRUG:** Immunotherapy
- **PROCEDURE:** Standard of care

## Key facts

- **NCT ID:** NCT04724928
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-29
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-05
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04724928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04724928, "Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04724928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*